What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy
In a 24-week trial of 22 patients, OncoSec saw a 41% response rate
OncoSec (ONCS) - Get Report is one of scores of companies trying to find a solution to a biologic roadblock limiting the efficacy of checkpoint inhibitors. If OncoSec continues development of its IL-12 melanoma immunotherapy, it will join a developing field that already includes Merck (MRK) - Get Report and Bristol-Myers Squibb (BMY) - Get Report .
READ THE FULL STORY HERE:
Biotech Stock Mailbag:
OncoSec Medical and the Quest to Turn Cold Tumors Hot
This article was written by a staff member of TheStreet.
